Le Lézard
Classified in: Health
Subject: FDA

Additive Orthopaedics Announces FDA Clearance of their Patient Specific 3D Printed Bone Segments for the Global Extremities Market


LITTLE SILVER, N.J., May 16, 2018 /PRNewswire/ -- Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, today announced that is has received FDA 510(k) clearance for its Patient Specific 3D Printed Bone Segments, to address internal bone fixation in the ankle and foot.    

Additive Orthopaedics Logo (PRNewsfoto/Additive Orthopaedics, LLC.)

According to Greg Kowalczyk, President of Additive Orthopaedics, "This is a tremendous milestone for orthopaedics and the obvious trend towards patient specific 3D printed implants.  In cases of implant revision, limb salvage, and trauma, often there are no clinically available devices to address the patient's condition.  This is where 3D printed patient specific implants are making significant clinical impacts."

According to Brian McLaughlin, VP of Engineering and Operations, "Our lattice structures are proving to be the next generation design as opposed to the older, more open, types of structures that rely on biologics for osteosynthesis.  In several patients, our lattice structures have shown close to 90% boney in-growth after 6 months using no biologics. We are excited to now offer these as patient specific solutions."

The Company has seen over 1000 devices implanted since their commercial launch in early 2017.   The Company has recently closed a Series B Round of $1M.  

About Additive Orthopaedics, LLC.
Additive Orthopaedics is an early stage orthopaedic company focused on the integration of advanced manufacturing and biologics for the benefit of a better patient outcome. 

Contact:
Greg Kowalczyk
732.882.6633
[email protected]

SOURCE Additive Orthopaedics, LLC.


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: